Fig. 2From: Emerging therapies for non-small cell lung cancerChord diagrams for sensitive and resistant mutations regarding ALK-TKIs. Both preclinical data and clinical reported cases (preferred) were enrolled to determine the efficacy of ALK-TKIs to different ALK-dependent mutations. Crizotinib had smallest sensitive mutation profiles compared to lorlatinib while opposite in resistant profiles. a Mutation profiles showed responsiveness to different ALK-TKIs. b Mutation profiles reported to be resistant to different ALK-TKIsBack to article page